{
    "clinical_study": {
        "@rank": "92292", 
        "arm_group": [
            {
                "arm_group_label": "Solution B (balance PD solution)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)"
            }, 
            {
                "arm_group_label": "Solution A (conventional PD solution)", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the biocompatibility of the peritoneal dialysis (PD) solution balance in\n      comparison to the conventional PD solution in APD(automated peritoneal dialysis) patients\n      using the APD cycler sleep\u2022safe."
        }, 
        "brief_title": "The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Equivalence of the investigational PD solution balance regarding fluid status compared to\n      the conventional PD solution.\n\n      Effects of balance on inflammation and systemic advanced glycation end products formation.\n\n      Effects of balance on peritoneal and total urea clearance, on peritoneal and total\n      creatinine clearance and on ultrafiltration, on residual diuresis and on cholesterol levels.\n\n      Safety of the investigational PD solution balance and the conventional PD solution as a\n      control drug.\n\n      The mesothelial cell mass assessed by Cancer Antigen 125 is affected by the use of the type\n      of PD solution in APD patients using sleep\u2022safe. Treating patients with the PD solution\n      balance leads to not more than 1 litre difference in hydration in comparison to the\n      conventional PD solution which is considered as clinically not relevant regarding blood\n      pressure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  APD patient \u2265 18 years\n\n          -  Prevalent patient with at least 3 months experience on APD prior to inclusion\n\n          -  Patient is trained on and being treated with the sleep\u2022safe APD cycler\n\n          -  Patient treated on APD exclusively with registered conventional PD  solutions CAPD 2,\n             CAPD 3, CAPD 4, CAPD 17, CAPD 18 or CAPD 19 for at least 8 weeks prior to inclusion\n\n          -  Patient is on stable diuretic treatment e.g no change in diuretic treatment within\n             the last 30 days prior to inclusion\n\n          -  Informed consent signed and dated by study patient and investigator/authorised\n             physician\n\n          -  Ability to understand the nature and requirements of the study\n\n        Exclusion Criteria:\n\n          -  Peritonitis treatment \u00a3 4 weeks preceding inclusion\n\n          -  APD patients treated with IPD modality (intermittent peritoneal dialysis)\n\n          -  Malignant disease without remission\n\n          -  Patients with artificial joints, amputations, stents, or pacemaker\n\n          -  Patients with congestive heart failure or coronary artery disease NYHA (New  York\n             Heart Association) III and higher\n\n          -  Active HBV (hepatitis B virus)or HCV(hepatitis C virus)infection- HIV positive\n\n          -  Participation in an interventional clinical study during the preceding 30 days\n\n          -  Any condition which could interfere with the patient's ability to comply with the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753154", 
            "org_study_id": "PD-NL-04-EU"
        }, 
        "intervention": [
            {
                "arm_group_label": "Solution B (balance PD solution)", 
                "description": "balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium", 
                "intervention_name": "Solution B (balance PD solution)", 
                "intervention_type": "Drug", 
                "other_name": "Balance"
            }, 
            {
                "arm_group_label": "Solution A (conventional PD solution)", 
                "description": "Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)", 
                "intervention_name": "Solution A (conventional PD solution)", 
                "intervention_type": "Drug", 
                "other_name": "CAPD 2, CAPD 3, CAPD 4, CAPD 17, CAPD 18 and CAPD 19"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peritoneal Dialysis", 
            "Biocompatible dialysis solution", 
            "Hydration status", 
            "Residual renal function", 
            "Body composition monitor", 
            "Bioimpedance spectroscopy", 
            "Cancer antigen 125"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gda\u0144sk,", 
                        "country": "Poland"
                    }, 
                    "name": "Centrum Dializ Fresenius Nephrocare"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland"
                    }, 
                    "name": "Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u0141\u00f3d\u017a", 
                        "country": "Poland"
                    }, 
                    "name": "Uniwersytecki Szpital Kliniczny nr 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albacete", 
                        "country": "Spain"
                    }, 
                    "name": "Complejo hospitalario universitario de Albacete"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Puerta de Hierro"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Fundaci\u00f3n Hospital Alcorc\u00f3n"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Poland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis", 
        "overall_official": {
            "affiliation": "Ospedale Umberto Oo, 30174 Mestre, Italy", 
            "last_name": "Mariano Feriani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Poland: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The appearance rate is defined as the sum of the amount of CA125 determined in each outflow bag (concentration of CA125 in outflow multiplied with outflow volume) divided by the real cumulative dwell time of all dwells performed on the day of the 24-hour dialysate collection.", 
            "measure": "CA 125 (cancer antigen 125) appearance rate in the 24 hours effluent and estimated hydration", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fresenius Medical Care Deutschland GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fresenius Medical Care Deutschland GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}